Lupin Receives U.S. FDA Approval for Amifampridine

Lupin Limited today announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Amifampridine Tablets, 10 mg. Amifampridine Tablets, 10 mg, bioequivalent to the reference listed drug (RLD), Firdapse Tablets, 10 mg, of Catalyst Pharmaceuticals, Inc., for the indication in the approved labeling. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic ***** the First-To-File, Lupin Is Eligible for 180-Day Shared Generic Exclusivity Opinion : This news will have positive effect on the stock price. Disclaimer : This is not a buy,sell or hold recommendation. I do not hold this stock.